1796

GeneFerm BiotechnologyTPEX:1796 Stock Report

Market Cap

NT$1.4b

7D

4.5%

1Y

54.5%

Updated

20 Sep, 2021

Data

Company Financials
1796 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

1796 Overview

GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for GeneFerm Biotechnology
Historical stock prices
Current Share PriceNT$34.00
52 Week HighNT$20.10
52 Week LowNT$42.20
Beta1.05
1 Month Change2.41%
3 Month Change-0.59%
1 Year Change54.55%
3 Year Change-19.05%
5 Year Change-57.81%
Change since IPO-62.39%

Recent News & Updates

Apr 16
GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Mar 12
Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Shareholder Returns

1796TW Personal ProductsTW Market
7D4.5%-1.3%-1.1%
1Y54.5%-17.0%33.6%

Return vs Industry: 1796 exceeded the TW Personal Products industry which returned -17% over the past year.

Return vs Market: 1796 exceeded the TW Market which returned 33.6% over the past year.

Price Volatility

Is 1796's price volatile compared to industry and market?
1796 volatility
1796 Beta1.05
Industry Beta0.58
Market Beta1

Stable Share Price: 1796 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 1796's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/an/ahttps://www.geneferm.com

GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company offers a range of raw materials, such as fermented microbial, fungi, and fruits and vegetables products; probiotics; and herbal extracts and animal derived peptides and powders. It also provides ODM, as well as fermentation toll manufacturing services to companies for the development and manufacture of dietary supplements, functional foods, health food products, and various applications.

GeneFerm Biotechnology Fundamentals Summary

How do GeneFerm Biotechnology's earnings and revenue compare to its market cap?
1796 fundamental statistics
Market CapNT$1.39b
Earnings (TTM)NT$31.96m
Revenue (TTM)NT$431.45m

43.4x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1796 income statement (TTM)
RevenueNT$431.45m
Cost of RevenueNT$272.04m
Gross ProfitNT$159.40m
ExpensesNT$127.44m
EarningsNT$31.96m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.96
Gross Margin36.95%
Net Profit Margin7.41%
Debt/Equity Ratio54.3%

How did 1796 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

9%

Payout Ratio

Valuation

Is GeneFerm Biotechnology undervalued compared to its fair value and its price relative to the market?

43.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1796 (NT$34) is trading above our estimate of fair value (NT$1.51)

Significantly Below Fair Value: 1796 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1796 is poor value based on its PE Ratio (43.4x) compared to the TW Personal Products industry average (15x).

PE vs Market: 1796 is poor value based on its PE Ratio (43.4x) compared to the TW market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1796's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1796's PB Ratio (1.9x) is in line with the TW Personal Products industry average.


Future Growth

How is GeneFerm Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneFerm Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has GeneFerm Biotechnology performed over the past 5 years?

-59.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1796 has high quality earnings.

Growing Profit Margin: 1796 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 1796's earnings have declined by 59.6% per year over the past 5 years.

Accelerating Growth: 1796 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 1796 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).


Return on Equity

High ROE: 1796's Return on Equity (4.5%) is considered low.


Financial Health

How is GeneFerm Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 1796's short term assets (NT$803.2M) exceed its short term liabilities (NT$440.9M).

Long Term Liabilities: 1796's short term assets (NT$803.2M) exceed its long term liabilities (NT$157.4M).


Debt to Equity History and Analysis

Debt Level: 1796's debt to equity ratio (54.3%) is considered high.

Reducing Debt: 1796's debt to equity ratio has increased from 26.1% to 54.3% over the past 5 years.

Debt Coverage: 1796's debt is well covered by operating cash flow (20.7%).

Interest Coverage: 1796's interest payments on its debt are well covered by EBIT (6x coverage).


Balance Sheet


Dividend

What is GeneFerm Biotechnology current dividend yield, its reliability and sustainability?

0.24%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1796's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).

High Dividend: 1796's dividend (0.24%) is low compared to the top 25% of dividend payers in the TW market (5.25%).


Stability and Growth of Payments

Stable Dividend: 1796 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 1796 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 1796 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1796's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

GeneFerm Biotechnology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.2%.


Top Shareholders

Company Information

GeneFerm Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: GeneFerm Biotechnology Co., Ltd.
  • Ticker: 1796
  • Exchange: TPEX
  • Founded: 1999
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$1.387b
  • Shares outstanding: 40.79m
  • Website: https://www.geneferm.com

Location

  • GeneFerm Biotechnology Co., Ltd.
  • Nangang Software Park
  • Building F, 4F-3
  • Taipei City
  • 11503
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 08:32
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.